FrontPage is India's Stock Market Social Network
Join 50,000+ Traders and Investors

SMSLIFE

734.85
+7.35 (1.01%)
Updated 03:28 23/07 IST

SMSLIFE Buy or Sell - FrontPage Forums

1 Users have submitted 1 trade ideas of Rs. 157,050.5 for SMSLIFE
Disclaimer
100% Bullish
0% Bearish

SMSLIFE Buy or Sell - Brokerage Reports

No. of reports in last year
0
No. of analysts
0
Average Consensus Forecast
Consensus Potential
0.00%
See SMSLIFE Share Price Targets >>

SMSLIFE Ratings

Long term SMSLIFE rating by FrontPage users
0/5 (0 Ratings)0
Find answers to all your questions on live SMSLIFE message board: Is SMSLIFE buy or sell? Should I buy SMSLIFE shares? Why are SMSLIFE shares falling? Should I invest in SMSLIFE stock?

  1. Home
  2. SMSLIFE Forum

SMSLIFE Share Price Discussion


Type
Buy
Instrument
SMSLIFE
Entry Price
₹766.1
Price@Trade
₹765.8
Target Price
₹1,066.1
Stop Price
₹566.1
Valid Till
Jul 1, 2022 3:20 AM
Margin
₹157,050.5 approx for 205 Qty
Status
Waiting for entry

Like
Reply
swap_vert
Trade

Sms Life at 760
Above 729 good for 840

Like
Reply (2)
See all replies

SMSLIFE - 3572724
You give positive newes

5days back

Type
Buy
Instrument
SMSLIFE
Entry Price
₹764.3
Price@Trade
₹764.3
Target Price
₹1,000
Stop Price
₹750
Valid Till
Jun 21, 2022 3:20 AM
Margin
₹764.3 approx for 1 Qty
Status
Stoploss Hit
Exit Price
₹750
Net P&L
-₹14.3 (-1.87%)

Like
Reply (1)
swap_vert
Trade
See all replies
TrackerBot @trackerbot
Jun 21 5:06 AM

Update
Stoploss Hit
Exit Price
₹750

Type
Buy
Instrument
SMSLIFE
Entry Price
₹705.3
Price@Trade
₹705.3
Target Price
₹730
Stop Price
₹688
Valid Till
Jun 25, 2021 3:20 AM
Margin
₹141,060 approx for 200 Qty
Status
Stoploss Hit
Exit Price
₹688
Net P&L
-₹3,460 (-2.45%)
Like
Reply (1)
swap_vert
Trade
See all replies
TrackerBot @trackerbot
Jun 18 3:58 AM

Update
Stoploss Hit
Exit Price
₹688

Type
Buy
Instrument
SMSLIFE
Entry Price
₹612.5
Price@Trade
₹612.5
Target Price
₹625
Stop Price
₹600
Valid Till
Jun 1, 2022 3:20 AM
Margin
₹612,500 approx for 1000 Qty
Status
Stoploss Hit
Exit Price
₹600
Net P&L
-₹12,500 (-2.04%)
Like
Reply (1)
swap_vert
Trade
See all replies
TrackerBot @trackerbot
Jun 1 3:38 AM

Update
Stoploss Hit
Exit Price
₹600

Type
Buy
Instrument
SMSLIFE
Entry Price
₹354
Price@Trade
₹354
Target Price
₹417
Stop Price
₹300
Valid Till
Jun 17, 2020 3:20 AM
Margin
₹354 approx for 1 Qty
Status
Stoploss Hit
Exit Price
₹300
Net P&L
-₹54 (-15.25%)
Like
Reply (1)
swap_vert
Trade
See all replies
TrackerBot @trackerbot
Jun 16, 2020 7:20 AM

Update
Stoploss Hit
Exit Price
₹300

SMSLIFE - chart - 723285
LONG TERM INVESTMENT CALL DATE - 19/04/2020
BUY SMSLIFE (LIMTED QTY)
CMP 316
STOP LOSS 300
TARGET 346 370 410 450 ++
Like
Reply

SMS Lifesciences: The U.S. FDA ban on Ranitidine drugs from the U.S. market and the lockdown due to Covid-19 can impact the revenue of the company.
1
Reply
N
Reputation: 14,803 • Sep 30, 2019 7:53 AM
Ranitidine controversy: Which Indian pharma companies stand to lose?
Moneycontrol
Like
Reply
Like
Reply
Join FrontPage
FrontPage is India's favorite stock discussions community
Join 2,00,000 Indian traders and discuss trades, strategies, news & views on any stock.
  • SMSLIFE - Share Price - Fundamentals

    keyboard_arrow_down
    Market Capitalization166.67
    Enterprise Value204.17
    Price to Earnings17.56
    Price to Book Value1.59
    Return on Capital Employed0.09
    Return on Equity0.07
    Face Value10
    Dividend YieldNA
  • SMSLIFE Share Price - Historical (₹)

    keyboard_arrow_down
    DateOpenHighLowClose
    Jul 23725759723.05733.6
    Jul 22725.65741.9723.55727.5
    Jul 20732745.75716.9725.65
    Jul 19748748721.9730.95
    Jul 16756.05757.9744751.05
  • SMSLIFE Share Price - Daily Moving Averages (DMA)

    keyboard_arrow_down
    20 Day Moving Average₹750.95
    30 Day Moving Average₹730.18
    50 Day Moving Average₹683.66
    100 Day Moving Average₹619.51
    200 Day Moving Average₹609.44
  • SMSLIFE - Profit And Loss

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Revenue213.45217.54-0.02
    Operating Profit13.2128.45-0.54
    Profit Before Tax6.418.47-0.65
    Net Income6.512.94-0.5
  • SMSLIFE - Balance Sheet

    keyboard_arrow_down
    CONSOLIDATEDMar-19Mar-18 % Change
    Shareholder's Funds104.9888.40.19
    Total Liabilities145.7290.140.62
    Total Assets250.7178.540.4
  • SMSLIFE - Ratios

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17
    Return on Assets0.040.07
    Return on Equity0.070.16
    Return on Capital Employed0.09NA
  • SMSLIFE - 3 year Growth

    keyboard_arrow_down
    3 Year CAGR Growth in RevenueNA
    3 Year CAGR Growth in Operating ProfitNA
    3 Year CAGR Growth in EBIDTANA
    3 Year CAGR Growth in Net IncomeNA
    3 Yr CAGR Growth - Diluted EPSNA
  • SMSLIFE - 5 year Growth

    keyboard_arrow_down
    5 Year CAGR Growth in RevenueNA
    5 Year CAGR Growth in Operating ProfitNA
    5 Year CAGR Growth in EBIDTANA
    5 Year CAGR Growth in Net IncomeNA
    3 Yr CAGR Growth - Diluted EPSNA
  • SMSLIFE - Recent News

    keyboard_arrow_down
    NewsBot
    Sep 30, 2019 7:53 AM
    Ranitidine controversy: Which Indian pharma companies stand to lose?
    Moneycontrol
  • SMSLIFE - Related Communities

    keyboard_arrow_down
    Sun Pharmaceutical Industries Ltd. NS...
    Cipla Ltd. NSE: CIPLA | BSE: 500087 |...
    Aurobindo Pharma Ltd. NSE: AUROPHARMA...
    Biocon Ltd. NSE: BIOCON | BSE: 532523...
    Lupin Ltd. NSE: LUPIN | BSE: 500257 |...
    Dr. Reddy's Laboratories Ltd. NSE: DR...
    Glenmark Pharmaceuticals Ltd. NSE: GL...
    Divi's Laboratories Ltd. NSE: DIVISLA...
    Piramal Enterprises Ltd. NSE: PEL | B...
    Cadila Healthcare Ltd. NSE: CADILAHC ...
SOURCE: Data from D'Market via Quandl. Intraday data delayed 15 minutes.
DISCLAIMER: Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and FrontPage will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein.

PrivacyTerms
FrontPage © 2020